Skip to main content

Table 3 Ejection Fraction Data for Participants Hospitalized with Heart Failure*

From: Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone

 

Chlorthalidone Treatment Group

Doxazosin Treatment Group

Total

Participants with hospitalized heart failure

245

296

541

Hospitalized heart failure participants reviewed

134

144

278

Total reviewed heart failure participants with quantitative ejection fractions

46

59

105

   By cardiac catheterization (%)

11 (23.9)

21 (35.6)

32 (30.5)

   By echocardiogram (%)

33 (71.7)

37 (62.7)

70 (66.7)

   Method not given (%)

2 (4.3)

1 (1.7)

3 (2.9)

Ejection fraction (%)

   

1–30%

15 (32.6)

27 (45.8)

42 (40.0)

31–40%

14 (30.4)

14 (23.7)

28 (26.7)

41–50%

9 (19.6)

7 (11.9)

16 (15.2)

51–60%

3 (6.5)

10 (16.9)

13 (12.4)

>60%

5 (10.9)

1 (1.7)

6 (5.7)

  1. *Evaluation of documentation for ejection fractions was completed in July, 1999, 6 months prior to the decision to discontinue the doxazosin arm of ALLHAT. Total numbers of events and participants with heart failure in Table 3 are based on data at the time of review. Event documentation which referred to ejection fraction measurements but which did not provide numeric values was excluded from this tally. Ejection fraction for a participant is based upon the earliest post-randomization heart failure hospitalization with quantitative ejection fraction information provided.